Kim Sinae, Song Jin Hoi, Kim Seokho, Qu Peng, Martin Betty K, Sehareen Waheed S, Haines Diana C, Lin Pengnian C, Sharan Shyam K, Chang Suhwan
Department of Biomedical Sciences, Department of Physiology, University of Ulsan School of Medicine, Seoul, South Korea.
Aging Research Center, Korea Research Institute of Bioscience & Biotechnology, Taejeon, South Korea.
Oncotarget. 2016 Mar 8;7(10):11094-112. doi: 10.18632/oncotarget.7150.
The oncogenic role of microRNA-155 (miR-155) in leukemia is well established but its role in other cancers, especially breast cancer, is gradually emerging. In this study we examined the effect of mir-155 loss in a well-characterized spontaneous breast cancer mouse model where Brca1 and Trp53 are deleted by K14-Cre. miR-155 is known to be up-regulated in BRCA1-deficient tumors. Surprisingly, complete loss of miR-155 (miR-155ko/ko) did not alter the tumor free survival of the mutant mice. However, we found increased infiltration of myeloid derived suppressor cells (MDSCs) in miR-155 deficient tumors. In addition, cytokine/chemokine array analysis revealed altered level of cytokines that are implicated in the recruitment of MDSCs. Mechanistically, we identified C/EBP-β, a known miR-155 target, to regulate the expression of these cytokines in the miR-155-deficient cells. Furthermore, using an allograft model, we showed that inhibition of miR-155 in cancer cells suppressed in vivo growth, which was restored by the loss of miR-155 in the microenvironment. Taken together, we have uncovered a novel tumor suppressive function of miR-155 in the tumor microenvironment, which is also dependent on miR-155 expression in the tumor cells. Because of the oncogenic as well as tumor suppressive roles of miR-155, our findings warrant caution against a systemic inhibition of miR-155 for anticancer therapy.
微小RNA-155(miR-155)在白血病中的致癌作用已得到充分证实,但其在其他癌症,尤其是乳腺癌中的作用正逐渐显现。在本研究中,我们在一个特征明确的自发性乳腺癌小鼠模型中检测了miR-155缺失的影响,该模型中Brca1和Trp53通过K14-Cre被敲除。已知miR-155在BRCA1缺陷型肿瘤中上调。令人惊讶的是,miR-155完全缺失(miR-155ko/ko)并未改变突变小鼠的无瘤生存期。然而,我们发现miR-155缺陷型肿瘤中髓源性抑制细胞(MDSC)的浸润增加。此外,细胞因子/趋化因子阵列分析显示与MDSC募集相关的细胞因子水平发生了改变。从机制上讲,我们确定了一个已知的miR-155靶点C/EBP-β来调节miR-155缺陷型细胞中这些细胞因子的表达。此外,使用同种异体移植模型,我们表明抑制癌细胞中的miR-155可抑制体内生长,而微环境中miR-155的缺失可恢复这种生长。综上所述,我们发现了miR-155在肿瘤微环境中的一种新的肿瘤抑制功能,这也依赖于肿瘤细胞中miR-155的表达。由于miR-155具有致癌和肿瘤抑制双重作用,我们的研究结果提醒人们在抗癌治疗中要谨慎对待对miR-155的全身性抑制。